Utilisation de complexes de cuivre impliquant des dérivés de 2-phényl-3-hydroxy-4(1H)-quinolinone et 1,10-phénanthroline pour la préparation de médicaments pour le traitement des maladies tumorales
The utilization of the copper complexes in the oxidation state +II and their crystal-solvates having the general formula [Cu(qui)(R n phen)]X, and expressed by the structural formula (I), where the symbol qui stands for the 2-phenyl-3-hydroxy-4(1H)-quinolinonate anion(1-), symbol R n , where n = 1-4, stands for a substituent or substituents on 1,10-phenathroline (phen), where R1 is a substituent independently chosen from the group of: hydrogen, 4-methyl, 5-methyl, 5-nitro, 5-chloro, if R1 is 5-methyl, then R2 is 6-methyl, if R1 is 4-phenyl, then R2 is 7-phenyl, if R1 is 3-methyl, then R2 is 4-methyl, R3 is 7-methyl and R4 is 8-methyl, expressed by the specific formulas as [Cu(qui)(4-methylphen)]X, [Cu(qui)(5-methylphen)]X, [Cu(qui)(5-nitrophen)]X, [Cu(qui)(5-chlorophen)]X, [Cu(qui)(5,6-dimethylphen)]X, [Cu(qui)(4,7-diphenylphen)]X, [Cu(qui)(3,4,7,8-tetramethylphen)]X, and the symbol X stands for a monoanion independently chosen from the group of: F - , Cl - , Br - , I - , NO 3 - , BF 4 - , BPh 4 - , HCOO - , CH 3 COO - , ClO 4 - , HSO 4 - ； for the preparation of drugs for the treatment of human lung carcinoma and/or human cervix epitheloid carcinoma and/or human malignant melanoma and/or human ovarian carcinoma and/or human cisplatin- resistant ovarian carcinoma and/or human prostate carcinoma.
